We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
ImpediMed is a medical devices business based in Australia. ImpediMed shares (IPD) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. ImpediMed has a trailing 12-month revenue of around $10 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Best overall broker
Our top pick for
Best low-cost broker
| 52-week range | $0.056 - $0.205 |
|---|---|
| 50-day moving average | $0.0982 |
| 200-day moving average | $0.1449 |
| Target price | $0.32 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.013 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.06
| 1 week (2022-06-21) | -1.64% |
|---|---|
| 1 month (2022-05-27) | -27.71% |
| 3 months (2022-03-28) | -58.62% |
| 6 months (2021-12-24) | -65.71% |
| 1 year (2021-06-28) | -45.45% |
|---|---|
| 2 years (2020-06-26) | -7.69% |
| 3 years (2019-06-28) | -47.28% |
| 5 years (2017-06-28) | -91.91% |
| Revenue TTM | $10 million |
|---|---|
| Gross profit TTM | $6.8 million |
| Return on assets TTM | -26.24% |
| Return on equity TTM | -45.65% |
| Profit margin | -191.38% |
| Book value | 0.033 |
| Market capitalisation | $108.5 million |
TTM: trailing 12 months
We're not expecting ImpediMed to pay a dividend over the next 12 months.
ImpediMed 's shares were split on a 102:100 basis on 1 June 2009. So if you had owned 100 shares the day before the split, the next day you would own 102 shares. This wouldn't directly have changed the overall worth of your ImpediMed shares – just the quantity. However, indirectly, the new 2% lower share price could have impacted the market appetite for ImpediMed shares which in turn could have impacted ImpediMed 's share price.
Over the last 12 months, ImpediMed 's shares have ranged in value from as little as $0.056 up to $0.205. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while ImpediMed 's is 3.0713. This would suggest that ImpediMed 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was incorporated in 1999 and is headquartered in Pinkenba, Australia.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
Steps to owning and managing Leo lithium shares.
Steps to owning and managing Besra Gold shares.
Steps to owning and managing The Lottery Corporation shares.
Steps to owning and managing Endeavour Group shares.
